Avillion notes that Pfizer Received a Positive CHMP Opinion for BOSULIF®

Avillion notes that Pfizer have received a positive CHMP opinion for BOSULIF® (bosutinib) for treating newly-diagnosed Ph+ chronic myelogenous leukemia.

The filing is based on the successful BFORE Phase 3 study conducted by Avillion under a collaborative development agreement with Pfizer.

Please read the full press release here.

TwitterLinkedInEmailPrint